Abstract 1511P
Background
Gemcitabine-based adjuvant chemotherapy (aGC) is a therapeutic mainstay after surgery for pancreatic ductal adenocarcinoma (PDAC), but relevant efficacy predictors are still lacking. Intratumoral gram-negative bacteria can suppress response to aGC. We assessed the effect of intratumoral bacterial colonization on aGC-efficacy and examined whether peri-operative antibiotic treatment (ABT) improved patient outcome.
Methods
Intratumoral bacteria were detected by immunohistochemistry (IHC) for lipopolysaccharide (gram-negative) and lipoteichoic acid (gram-positive) in the samples of 342 resected PDAC patients treated with either aGC or none / non-gemcitabine-based adjuvant chemotherapy (naGC). Preoperative ABT was defined as ABT for more than 24 hours within 30 days before resection. Postoperative ABT was defined as ABT for more than 24 hours within 30 days after resection. Data of 177 patients from the TCGA database were used for validation.
Results
High bacterial colonization (bacHI) conferred worse disease-free survival (DFS, 9.4 vs 19.1 months, p<0.001) and overall survival (OS, 19.4 months vs 34.0 months, p<0.001) in aGC patients, but made no statistical difference in naGC patients (p=0.66 and p=0.42). BacHI did not correlate with the tumors transcriptional subtype, pre-operative ATB, bile duct interventions or other prognostic clinicopathological variables. Pre-operative ABT did not affect patient outcome, irrespective of adjuvant chemotherapy. Post-operative ABT significantly improved patientś DFS (17.5 vs. 10.8 months, p<0.001) and OS (37.8 vs. 20.6 months, p<0.001) in the aGC cohort, but not in the naGC cohort (p=0.60 and p=0.97). The findings were confirmed by inverse propensity score weighted multivariable Cox regression analyses and in the external validation cohort.
Conclusions
High intratumoral bacterial abundance is a negative predictor of adjuvant gemcitabine efficacy in PDAC but can be overcome by post-operative antibiotic treatment prior adjuvant therapy. Detection of intratumoral bacteria in resection specimens by IHC may guide the use of antibiotics to improve therapy response and patient outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18